期刊文献+

培美曲塞联合顺铂与多西他赛联合顺铂治疗非小细胞肺癌的疗效对比 被引量:16

Efficacy comparison between pemetrexed combined with cisplatin and docetaxel combined with cisplatin in treatment of non-small cell lung cancer
下载PDF
导出
摘要 目的对比分析培美曲塞(pemetrexed,MTA)联合顺铂(cisplatin,DDP)与多西他赛(docetaxel,TXT)联合顺铂(DDP)应用于非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗效果。方法选取2013年5月1日~2015年5月1日在安顺市人民医院接受化疗的50例NSCLC患者,随机分为MTA和TXT组,每组25例,并分别采用MTA联合DDP方案和TXT联合DDP方案进行治疗,治疗1个疗程总共21 d。对2种治疗方案的效果以及不良反应进行对比。结果经过治疗后,MTA组、TXT组的可溶性细胞间黏附因子-1(soluble intercellular adhesion molecule 1,s ICAM-1)和可溶性血管细胞粘附分子1(soluble vasccular cell adhesion molecule 1,s VCAM-1)水平明显降低(P<0.05),2组治疗后s ICAM-1和s VCAM-1水平无显著差异。治疗后MTA组的总有效率(20.00%)与TXT组(16.00%)比较,差异无统计学意义(χ2=0.136,P>0.05)。MTA组发生恶心呕吐、贫血、血小板降低、中性粒细胞降低、脱发的不良反应率(40.00%)低于TXT组(72.00%)(χ2=5.195,P<0.05)。结论 MTA联合DDP方案治疗NSCLC的效果与TXT联合DDP方案比较无明显差异,但不良反应发生率低。 Objective To compare efficacy of pemetrexed (MTA) combined with cisplatin (DDP) and docetaxel (TXT) combined with DDP in treatment of non-small cell lung cancer (NSCLC).Methods 50 patients with NSCLC from May 1, 2013 to May 1, 2015 in the hospital were seleced and randomly divided into two groups:MTA group (n=25) were received MTA combined with DDP, and TXT group(n=25) were received TXT combined with DDP, for a course of twenty-one days.After treatment, the efficacy of two therapy as well as adverse reactions were compared.ResuIts After treatment, the soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vasccular cell adhesion molecule 1 (sVCAM-1) levels in MTA group were significantly lower than those before treatment (P<0.05), but there were no statistical differences in TXT group, and the above two indicators in MTA group were lower than those in TXT group(P<0.05).There were no significant difference of total efficacy between MTA group and TXT group (20.00% vs.16.00%, χ2 =0.136,P>0.05).The adverse reaction of nausea and vomiting, anemia, low platelet count, neutropenia and alopecia in MTA group was lower than that in TXT group (40.00%vs.72.00%,χ2 =5.195,P<0.05).ConcIusion The efficacy of MTA combined with DDP and TXT combined with DDP in treatment of NSCLC is similar, but the adverse reactions of fomer one is lower.
出处 《中国生化药物杂志》 CAS 2015年第8期143-145,共3页 Chinese Journal of Biochemical Pharmaceutics
关键词 培美曲塞 非小细胞肺癌 多西他赛 顺铂 pemetrexed non-small cell lung cancer docetaxel cisplatin
  • 相关文献

参考文献5

二级参考文献58

  • 1刘联,王秀问,黎莉,张昕,张文东,于学军.含顺铂的三组联合化疗方案治疗晚期非小细胞肺癌的随机对照临床研究[J].癌症,2006,25(8):990-994. 被引量:93
  • 2毛友生,高燕宁,赫捷,张德超,程书钧.肺癌分子生物学特性与转移和预后的关系[J].中华肿瘤杂志,2006,28(8):632-634. 被引量:60
  • 3Bunyaviroch T, Coleman RE. PET evaluation of lung cancer. J Nucl Med, 2006,47 ( 3 ) :451 - 69.
  • 4Erasmus JJ, McAdams HP, Connolly JE. Solitary pulmonary nodules: part Ⅱ. Evaluation of the indeterminate nodule. RadioGraphics, 2000,20:59-66.
  • 5Dewan NA, Shehan C J, Reeb SD, et al. Likelihood of malignancy in a solitary pulmonary nodule. Chest, 1997,112:416 - 422.
  • 6Duhaylongsod FG, Lowe V J, Patz EF Jr, et al. Detection of primary and recurrent lung cancer by means of F-18fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg, 1995,110 : 130 - 139.
  • 7Henschke CI, Yankelevitz DF, Naidich DP, et al. CT screening for lung cancer: suspiciousness of nodules according to size on baseline scans. Radiology ,2004,231 : 164 - 168.
  • 8Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med, 2003,348:2500 -2507.
  • 9Birin O, Kaappetein AP, Bogers AL, et al. Meta-analysis of positron emission tomography and computed tomographyic imaging indetected mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thora surg, 2005,79:375 - 382.
  • 10Fischer BM, Mortensen J. The future in diagnosis and staging of lung cancer: positron emission tomography. Respiration, 2006,73 (3) :267 -76.

共引文献77

同被引文献135

  • 1梁万霞,赵宇,武永辉,梅新宽,钱和生.安罗替尼联合多西他赛对比安罗替尼二线治疗EGFR野生型的非小细胞肺癌的临床观察[J].湖南师范大学学报(医学版),2021,18(4):258-261. 被引量:9
  • 2胡立娟.培美曲塞与吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床效果对比观察[J].世界临床医学,2017,11(3):93-94. 被引量:17
  • 3黄镜,蔡锐刚,孟平均,张明娟,崔成旭,杨林,储大同,孙燕,王金万.紫杉醇联合顺铂治疗晚期食管鳞癌[J].中华肿瘤杂志,2004,26(12):753-755. 被引量:96
  • 4韩国容,蔡桂凤.顺铂腹腔化疗的药代动力学研究[J].中华妇产科杂志,1993,28(4):224-226. 被引量:15
  • 5Belani CP. Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxed[J].Lung Cancer,2005,50 (2) : 3-8.
  • 6Huosman C, Smit EF, Giaccone G, et al. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer., a review[J]. J Clin Oncol, 2000,18(21): 3722-3730.
  • 7Shepherd FA, Daneey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive cave in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy[J]. J Clin Oncol, 2000, 18 (10) ,2095-2103.
  • 8José Rodrigues-Pereira,Joo-Hang Kim,Manuel Magallanes,Dae Ho Lee,Jie Wang,Vinod Ganju,Luis Martínez-Barrera,Helen Barraclough,Maximiliano van Kooten,Mauro Orlando.??A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer(J)Journal of Thoracic Oncology . 2011 (11)
  • 9Mark A. Socinski,Robert N. Raju,Thomas Stinchcombe,Darren M. Kocs,Linda S. Couch,David Barrera,Steven R. Rousey,Janak K. Choksi,Robert Jotte,Debra A. Patt,Phillip O. Periman,Howard R. Schlossberg,Charles H. Weissman,Yunfei Wang,Lina Asmar,Sharon Pritchard,Jane Bromund,Guangbin Peng,Joseph Treat,Coleman K. Obasaju.??Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer(J)Journal of Thoracic Oncology . 2010 (12)
  • 10Siegel R,Naishadham D,Jemal A.Cancer statistics,2012.[J].CACancer J Clin,2012,62(1):10-29.

引证文献16

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部